TrimmTrack
Sign in

Pfizer (PFE) valuation

Run six valuation models on Pfizer with live data: DCF, Reverse DCF, Graham number, Monte Carlo, scenarios and sum-of-the-parts (NAV).

PFE
PFE

Pfizer

PFE · Healthcare

Current price

26,32 USD

You're trying every model for free, no account needed. Sign up to save your analyses →

Valuation

Market cap
$149.99B
PE (TTM | NTM | +1y)
34.63 | 9.10 | 9.10
Price / Sales
2.35
EV / EBITDA
8.03
Price / Book
1.76

Cash flow

FCF yield(2.19 / 26.32)
+8.32%
SBC-adjusted FCF yield
—
SBC impact
—

Margins & growth

Profit margin
+6.8%
Operating margin
+27.88%
Quarterly earnings (YoY)
—
Quarterly revenue (YoY)
—

Balance

Cash
$11.7B
Debt
$63.48B
Net position
-$51.78B

Dividend

Dividend yield
+6.46%
Payout ratio
+226.32%
Next payout
9/1/2026

Price (1 year)

+4.68%
$28.32

Revenue

estimate
Q2 23: $18.49BQ2 23Q3 23: $13.01BQ4 23: $13.49BQ4 23: $5.93BQ4 23Q1 24: $14.88BQ2 24: $13.28BQ3 24: $17.7BQ3 24Q2 25: $14.65BQ3 25: $16.65BQ4 25: $17.56BQ4 25Q1 26: $14.45BQ2 26: $15.03BQ2 26Q3 26 · estimate: $15.98BQ3 26$18.49B

EBITDA

Q2 25: $5.32BQ2 25Q3 25: $5.65BQ3 25Q4 25: $756MQ4 25Q1 26: $5.45BQ1 26Q2 26: $1.64BQ2 26$5.65B

Net income

Q2 23: $5.54BQ2 23Q3 23: $2.33BQ4 23: -$2.38BQ4 23Q4 23: -$3.37BQ1 24: $3.12BQ1 24Q2 24: $41MQ3 24: $4.47BQ3 24Q2 25: $2.91BQ3 25: $3.54BQ3 25Q4 25: -$1.65BQ1 26: $2.69BQ2 26: -$248MQ2 26$5.54B

Free cash flow

Q2 23: $73MQ2 23Q1 24: $386MQ2 25: -$1.2BQ2 25Q3 25: $4BQ4 25: $4.5BQ4 25Q1 26: $2.18BQ2 26: $302MQ2 26$4.5B

EPS

estimate
Q2 23: 0.97Q2 23Q3 23: 0.41Q4 23: -0.42Q4 23: -0.59Q4 23Q1 24: 0.55Q2 24: 0.01Q3 24: 0.78Q3 24Q2 25: 0.51Q3 25: 0.62Q4 25: -0.29Q4 25Q1 26: 0.47Q2 26: -0.04Q2 26Q3 26 · estimate: 0.77Q3 260.97

Cash & debt

CashDebt
Q2 23 · Cash: $2.17BQ2 23Q3 23 · Cash: $2.63BQ4 23 · Cash: $3.15BQ4 23Q4 23 · Cash: $2.85BQ1 24 · Cash: $719MQ1 24Q2 24 · Cash: $1.05BQ3 24 · Cash: $1.09BQ3 24Q2 25 · Cash: $1.64BQ2 25 · Debt: $60.93BQ3 25 · Cash: $1.34BQ3 25 · Debt: $60.85BQ3 25Q4 25 · Cash: $1.14BQ4 25 · Debt: $63.96BQ1 26 · Cash: $1.7BQ1 26 · Debt: $63.73BQ2 26 · Cash: $976MQ2 26 · Debt: $63.19BQ2 26$63.96B

Return of capital

DividendsBuybacks
Q2 23 · Buybacks: $0Q2 23Q2 25 · Dividends: $2.45BQ2 25Q3 25 · Dividends: $2.44BQ3 25Q4 25 · Dividends: $2.45BQ4 25Q1 26 · Dividends: $2.45BQ1 26Q2 26 · Dividends: $2.45BQ2 26$2.45B

Shares outstanding

Q2 23: 5.65BQ2 23Q3 23: 5.65BQ4 23: 5.65BQ2 24: 5.67BQ2 24Q3 24: 5.67BQ4 24: 5.67BQ2 25: 5.69BQ2 25Q2 25: 5.69BQ3 25: 5.69BQ3 25: 5.69BQ3 25Q4 25: 5.69BQ4 25: 5.69BQ1 26: 5.7BQ1 26Q2 26: 5.7BQ2 26: 5.7BQ2 265.7B

Stock-based compensation

Q2 23: $105MQ2 23Q1 24: $220MQ2 25: $203MQ2 25Q3 25: $201MQ4 25: $225MQ4 25Q1 26: $272MQ2 26: $249MQ2 26$272M

Operating expenses

R&DSG&A
Q2 23 · SG&A: $3.42BQ2 23Q3 23 · SG&A: $3.5BQ4 23 · SG&A: $3.28BQ4 23Q4 23 · SG&A: $4.58BQ1 24 · SG&A: $3.5BQ1 24Q2 24 · SG&A: $3.72BQ3 24 · SG&A: $3.24BQ3 24Q2 25 · R&D: $2.48BQ2 25 · SG&A: $3.42BQ3 25 · R&D: $2.55BQ3 25 · SG&A: $3.19BQ3 25Q4 25 · R&D: $3.21BQ4 25 · SG&A: $4.16BQ1 26 · R&D: $2.49BQ1 26 · SG&A: $2.96BQ2 26 · R&D: $2.81BQ2 26 · SG&A: $3.41BQ2 26$7.37B

Source: Yahoo Finance. Quarterly history grows automatically over time as new quarters are published.

Other comparisons

Johnson & Johnson vs Pfizer

Popular companies

AppleNvidiaTeslaMicrosoftAmazonAlphabet (Google)Meta PlatformsNetflixAMDPalantirBerkshire HathawayJPMorgan ChaseVisaMastercardWalt DisneyCoca-ColaPepsiCoMcDonald'sNikeStarbucksIntelBroadcomQualcommOracleSalesforceAdobePayPalUberAirbnbCoinbase